CHEVRON CORP — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that CHEVRON CORP filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $189.03B | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $202.79B | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $200.95B | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | $246.25B | Feb 21, 2025 |
| FY2023 | Dec 31, 2021 | $162.47B | Feb 26, 2024 |
| FY2022 | Dec 31, 2020 | $94.69B | Feb 23, 2023 |
| FY2021 | Dec 31, 2019 | $146.52B | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | $166.34B | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | $141.72B | Feb 21, 2020 |
| FY2018 | Dec 31, 2016 | $114.47B | Feb 22, 2019 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $184.43B | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $193.41B | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $196.91B | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | $235.72B | Feb 21, 2025 |
| FY2023 | Dec 31, 2021 | $155.61B | Feb 26, 2024 |
| FY2022 | Dec 31, 2020 | $94.47B | Feb 23, 2023 |
| FY2021 | Dec 31, 2019 | $139.87B | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | $158.90B | Feb 25, 2021 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $12.30B | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $17.66B | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $21.37B | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | $35.47B | Feb 21, 2025 |
| FY2023 | Dec 31, 2021 | $15.63B | Feb 26, 2024 |
| FY2022 | Dec 31, 2020 | ($5.54B) | Feb 23, 2023 |
| FY2021 | Dec 31, 2019 | $2.92B | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | $14.82B | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | $9.20B | Feb 21, 2020 |
| FY2018 | Dec 31, 2016 | ($497.00M) | Feb 22, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $427.00M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $353.00M | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $320.00M | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | $268.00M | Feb 21, 2025 |
| FY2023 | Dec 31, 2021 | $268.00M | Feb 26, 2024 |
| FY2022 | Dec 31, 2020 | $435.00M | Feb 23, 2023 |
| FY2021 | Dec 31, 2019 | $500.00M | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | $453.00M | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | $433.00M | Feb 21, 2020 |
| FY2018 | Dec 31, 2016 | $476.00M | Feb 22, 2019 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.13B | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $4.83B | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $4.14B | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | $4.31B | Feb 21, 2025 |
| FY2023 | Dec 31, 2021 | $4.01B | Feb 26, 2024 |
| FY2022 | Dec 31, 2020 | $4.21B | Feb 23, 2023 |
| FY2021 | Dec 31, 2019 | $4.14B | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | $3.84B | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | $4.11B | Feb 21, 2020 |
| FY2018 | Dec 31, 2016 | $4.31B | Feb 22, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $33.94B | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $31.49B | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $35.61B | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | $49.60B | Feb 21, 2025 |
| FY2023 | Dec 31, 2021 | $29.19B | Feb 26, 2024 |
| FY2022 | Dec 31, 2020 | $10.58B | Feb 23, 2023 |
| FY2021 | Dec 31, 2019 | $27.31B | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | $30.62B | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | $20.34B | Feb 21, 2020 |
| FY2018 | Dec 31, 2016 | $12.69B | Feb 22, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $324.01B | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $256.94B | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | $261.63B | Feb 21, 2025 |
| FY2023 | Dec 31, 2022 | $257.71B | Feb 26, 2024 |
| FY2022 | Dec 31, 2021 | $239.54B | Feb 23, 2023 |
| FY2021 | Dec 31, 2020 | $239.79B | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | $237.43B | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | $253.86B | Feb 21, 2020 |
| FY2018 | Dec 31, 2017 | $253.81B | Feb 22, 2019 |
| FY2017 | Dec 31, 2016 | $260.08B | Feb 22, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $131.84B | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $103.78B | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | $99.70B | Feb 21, 2025 |
| FY2023 | Dec 31, 2022 | $97.47B | Feb 26, 2024 |
| FY2022 | Dec 31, 2021 | $99.60B | Feb 23, 2023 |
| FY2021 | Dec 31, 2020 | $107.06B | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | $92.22B | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | $98.22B | Feb 21, 2020 |
| FY2018 | Dec 31, 2017 | $104.49B | Feb 22, 2019 |
| FY2017 | Dec 31, 2016 | $113.36B | Feb 22, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $186.45B | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $152.32B | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | $160.96B | Feb 21, 2025 |
| FY2023 | Dec 31, 2022 | $159.28B | Feb 26, 2024 |
| FY2022 | Dec 31, 2021 | $139.07B | Feb 23, 2023 |
| FY2021 | Dec 31, 2020 | $131.69B | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | $144.21B | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | $154.55B | Feb 21, 2020 |
| FY2018 | Dec 31, 2017 | $148.12B | Feb 22, 2019 |
| FY2017 | Dec 31, 2016 | $145.56B | Feb 22, 2018 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.57B | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $4.58B | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | $4.72B | Feb 21, 2025 |
| FY2023 | Dec 31, 2022 | $4.72B | Feb 26, 2024 |
| FY2022 | Dec 31, 2021 | $4.39B | Feb 23, 2023 |
| FY2021 | Dec 31, 2020 | $4.40B | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | $4.46B | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | $4.52B | Feb 21, 2020 |
| FY2018 | Dec 31, 2017 | $4.53B | Feb 22, 2019 |
| FY2017 | Dec 31, 2016 | $4.58B | Feb 22, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $205.37B | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $205.85B | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | $200.03B | Feb 21, 2025 |
| FY2023 | Dec 31, 2022 | $190.02B | Feb 26, 2024 |
| FY2022 | Dec 31, 2021 | $165.55B | Feb 23, 2023 |
| FY2021 | Dec 31, 2020 | $160.38B | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | $174.95B | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | $180.99B | Feb 21, 2020 |
| FY2018 | Dec 31, 2017 | $174.11B | Feb 22, 2019 |
| FY2017 | Dec 31, 2016 | $173.05B | Feb 22, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $8.18B | Feb 26, 2024 |
| FY2023 | Dec 31, 2022 | $17.68B | Feb 26, 2024 |
| FY2023 | Dec 31, 2021 | $5.64B | Feb 26, 2024 |
| FY2022 | Dec 31, 2020 | $5.60B | Feb 23, 2023 |
| FY2018 | Dec 31, 2018 | $9.34B | Feb 22, 2019 |
| FY2018 | Dec 31, 2017 | $4.81B | Feb 22, 2019 |
| FY2018 | Dec 31, 2016 | $6.99B | Feb 22, 2019 |
| FY2018 | Dec 31, 2015 | $11.02B | Feb 22, 2019 |
| FY2017 | Dec 31, 2014 | $12.79B | Feb 22, 2018 |
| FY2016 | Dec 31, 2013 | $16.25B | Feb 23, 2017 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Dec 31, 2021 | $25.68B | Feb 24, 2022 |
| FY2020 | Dec 31, 2020 | $25.68B | Feb 25, 2021 |
| FY2019 | Dec 31, 2019 | $18.73B | Feb 21, 2020 |
| FY2018 | Dec 31, 2018 | $23.73B | Feb 22, 2019 |
| FY2018 | Dec 31, 2017 | $30.23B | Feb 22, 2019 |
| FY2017 | Dec 31, 2016 | $32.49B | Feb 22, 2018 |
| FY2016 | Dec 31, 2015 | $27.07B | Feb 23, 2017 |
| FY2015 | Dec 31, 2014 | $15.96B | Feb 25, 2016 |
| FY2014 | Dec 31, 2013 | $11.96B | Feb 20, 2015 |
| FY2013 | Dec 31, 2012 | $6.09B | Feb 21, 2014 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 6 | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | 9 | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | 11 | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | 18 | Feb 21, 2025 |
| FY2023 | Dec 31, 2021 | 8 | Feb 26, 2024 |
| FY2022 | Dec 31, 2020 | (2) | Feb 23, 2023 |
| FY2021 | Dec 31, 2019 | 1 | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | 7 | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | 4 | Feb 21, 2020 |
| FY2018 | Dec 31, 2016 | 0 | Feb 22, 2019 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 6 | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | 9 | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | 11 | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | 18 | Feb 21, 2025 |
| FY2023 | Dec 31, 2021 | 8 | Feb 26, 2024 |
| FY2022 | Dec 31, 2020 | (2) | Feb 23, 2023 |
| FY2021 | Dec 31, 2019 | 1 | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | 7 | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | 4 | Feb 21, 2020 |
| FY2018 | Dec 31, 2016 | 0 | Feb 22, 2019 |
Dividends Paid
Cash dividends distributed to common shareholders during the period. Shown as a positive value despite being a cash outflow in the SEC filing.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $12.75B | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $11.80B | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $11.34B | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | $10.97B | Feb 21, 2025 |
| FY2023 | Dec 31, 2021 | $10.18B | Feb 26, 2024 |
| FY2022 | Dec 31, 2020 | $9.65B | Feb 23, 2023 |
| FY2021 | Dec 31, 2019 | $8.96B | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | $8.50B | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | $8.13B | Feb 21, 2020 |
| FY2018 | Dec 31, 2016 | $8.03B | Feb 22, 2019 |